Cypralis

7 articles about Cypralis

• Identification of synthetic, macrocyclic, orally bioavailable cyclophilin inhibitors with potent HCV activity, published in The Journal of Medicinal Chemistry

  9/17/2018

  A paper entitled ‘Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle’ by authors from Selcia, Cypralis and Gilead has been selected as a featured article by the editors of The Journal of Medicinal Chemistry. 

• Cypralis and Gilead Agree on License Terms Under Which Cypralis Will Hold Exclusive Development and Commercialization Rights to Certain Jointly-Owned 'Cyprolides' for Acute and Chronic Degenerative Diseases

  1/8/2018

  Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology.

• Cypralis to Present Pre-Clinical Data on Novel Cyclophilin D Inhibitor CC-1233 for Acute Pancreatitis at the American Pancreatic Association Meeting

  11/9/2017

  Cypralis, in collaboration with the University of Liverpool, will present in-vitro and in-vivo data obtained using novel cyclophilin inhibitor CC-1233 in models of acute pancreatitis at the American Pancreatic Association annual meeting in San Diego (Nov. 8-11th, 2017). 

• Cypralis Granted New Innovate UK Feasibility Stage Award To Develop Cyclophilin Inhibitors Targeting Fibrotic Diseases

  9/19/2017

• Cypralis Announces Grant Award From Alzheimer's Drug Discovery Foundation

  3/1/2017

• Selcia Limited, Cypralis And Gilead Publish Synthetic Macrocyclic Cyclophilin Inhibitors Inspired By Natural Product Sanglifehrin A

  2/10/2017

• Cypralis Release: Company Granted New Innovate UK Early Stage Award To Develop Cyclophilin D Inhibitors Targeting Degenerative Diseases

  1/23/2017